Dr Reddy’s Laboratories announced that the EMA’s committee recommended its Rituximab biosimilar Ituxredi for the European market. The decision will be reviewed by the European Commission for final approval. A separate application will be made to the UK MHRA. Earlier, the company received the EU GMP certificate for its manufacturing facility in Hyderabad.